Remove Documentation Remove FDA Remove Labelling Remove Workshop
article thumbnail

Under FDORA, FDA to Require Most Drug and Device Trials to Submit Diversity Action Plans

The FDA Law Blog

Livornese — Last month, Congress took a big step towards improving clinical trial diversity by requiring sponsors of most drug and device clinical studies to submit a diversity action plan when they submit key trial documents to the Food and Drug Administration (FDA). This guidance was finalized in 2020.

FDA 59
article thumbnail

Pharma 4.0™ Is Gaining Momentum and Driving Innovation

ISPE

™ started in 2015 at the ISPE Germany/Austria/Switzerland (D/A/CH) “Plug and Produce” workshop in Basel, Switzerland. ™, driven by the recognition that digital transformation offers a big chance to finally realize the US FDA’s Pharmaceutical Quality for the 21st Century Initiative to the full extent. to a pharma-specific Pharma 4.0™

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products.

article thumbnail

Challenges & Opportunities in Emerging Digital Health Technologies

ISPE

In December 2021, the US FDA issued a cross-center draft guidance with recommendations on the use of digital health technology tools (DHTTs) to acquire data remotely from participants in clinical investigations for medical products.